Outcome of living donor liver transplantation in patients of hepatic malignancy with metachronous adrenal gland metastasis: Can we achieve long term survival?

A. Thorat, S. Hsu, Horng-ren Yang, T. Chen, K. Poon, Ping-chun Li, L. Jeng
{"title":"Outcome of living donor liver transplantation in patients of hepatic malignancy with metachronous adrenal gland metastasis: Can we achieve long term survival?","authors":"A. Thorat, S. Hsu, Horng-ren Yang, T. Chen, K. Poon, Ping-chun Li, L. Jeng","doi":"10.31031/gmr.2018.02.000541","DOIUrl":null,"url":null,"abstract":"Hepatocellular carcinoma (HCC) is third most frequent cause of cancer-related deaths worldwide. Liver transplantation (LT) is a potentially curative treatment and is the best treatment option for patients with decompensated cirrhosis. Although advanced HCCs are considered as contraindication for LT due to dismal prognosis, certain patients of HCCs with solitary metastasis in adrenal gland without any other extra-hepatic disease can still be managed by local resection of the adrenal gland metastasis and sequential LT. Herein we present our experience of sequential 4 cases of HCC solitary metastasis to adrenal gland that were treated by local resection followed by LT. Materials and Methods: Database of 937 patients that underwent LT at china medical university hospital was retrospectively analyzed. Four HCC patients that had solitary adrenal metastasis were evaluated for the outcome after living donor liver transplantation (LDLT). Three patients were diagnosed to have HCC whereas one patient was diagnosed with unresectable cholangiocarcinoma on explant pathology. All the four patients had underlying cirrhosis with solitary adrenal metastasis without any extrahepatic spread of primary disease. The adrenal gland metastasis was confirmed by pre-LT PET scan. Results: Four patients (mean age, 53 years; M:F, 2:2) underwent LDLT for HCC with single adrenal metastasis (right adrenal gland=2 patients; and left adrenal gland=2 patients) . In three patients the adrenalectomy was performed during the recipient surgery whereas one patient underwent LDLT six months after the adrenal metastasis resection (Table 1). Follow up period ranged from 9 months to 59 months. Survival in first two patients was 52 and 59 months, respectively. The first patient developed lung metastatic and expired due to overwhelming sepsis at 52nd post-LT month. The second patient in this series continue to have recurrence free survival at 59 months post-LT. The survival in third and fourth patients was 28 months and 9 months, respectively. The fourth patient in addition had mixed HCC-cholangiocarcinoma on histopathological analysis. Conclusion: Limited extrahepatic metastasis due to HCC can still be resected and LT can be performed if liver resection not possible with a good overall survival. The adrenalectomy can be done as a single stage procedure during LT surgery without increasing the risk.","PeriodicalId":130011,"journal":{"name":"Gastroenterology: Medicine & Research","volume":"57 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology: Medicine & Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31031/gmr.2018.02.000541","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatocellular carcinoma (HCC) is third most frequent cause of cancer-related deaths worldwide. Liver transplantation (LT) is a potentially curative treatment and is the best treatment option for patients with decompensated cirrhosis. Although advanced HCCs are considered as contraindication for LT due to dismal prognosis, certain patients of HCCs with solitary metastasis in adrenal gland without any other extra-hepatic disease can still be managed by local resection of the adrenal gland metastasis and sequential LT. Herein we present our experience of sequential 4 cases of HCC solitary metastasis to adrenal gland that were treated by local resection followed by LT. Materials and Methods: Database of 937 patients that underwent LT at china medical university hospital was retrospectively analyzed. Four HCC patients that had solitary adrenal metastasis were evaluated for the outcome after living donor liver transplantation (LDLT). Three patients were diagnosed to have HCC whereas one patient was diagnosed with unresectable cholangiocarcinoma on explant pathology. All the four patients had underlying cirrhosis with solitary adrenal metastasis without any extrahepatic spread of primary disease. The adrenal gland metastasis was confirmed by pre-LT PET scan. Results: Four patients (mean age, 53 years; M:F, 2:2) underwent LDLT for HCC with single adrenal metastasis (right adrenal gland=2 patients; and left adrenal gland=2 patients) . In three patients the adrenalectomy was performed during the recipient surgery whereas one patient underwent LDLT six months after the adrenal metastasis resection (Table 1). Follow up period ranged from 9 months to 59 months. Survival in first two patients was 52 and 59 months, respectively. The first patient developed lung metastatic and expired due to overwhelming sepsis at 52nd post-LT month. The second patient in this series continue to have recurrence free survival at 59 months post-LT. The survival in third and fourth patients was 28 months and 9 months, respectively. The fourth patient in addition had mixed HCC-cholangiocarcinoma on histopathological analysis. Conclusion: Limited extrahepatic metastasis due to HCC can still be resected and LT can be performed if liver resection not possible with a good overall survival. The adrenalectomy can be done as a single stage procedure during LT surgery without increasing the risk.
肝恶性肿瘤伴异时性肾上腺转移患者活体供肝移植的疗效:能否实现长期生存?
肝细胞癌(HCC)是全球癌症相关死亡的第三大常见原因。肝移植(LT)是一种潜在的治愈治疗,是失代偿性肝硬化患者的最佳治疗选择。虽然晚期HCC因预后不佳被认为是肝移植的禁忌症,但某些HCC伴肾上腺孤立转移而无肝外病变的患者,仍然可以通过局部切除肾上腺转移并序次肝移植进行治疗。在此,我们报告了连续4例HCC孤立转移至肾上腺,局部切除后行肝移植治疗的经验。回顾性分析中国医科大学附属医院937例肝移植患者的资料。对4例单发肾上腺转移的肝癌患者进行活体肝移植(LDLT)后的预后评估。3例患者被诊断为HCC, 1例患者被诊断为不可切除的胆管癌。所有4例患者均有原发性肝硬化伴单发肾上腺转移,无原发性疾病肝外扩散。经lt前PET扫描证实肾上腺转移。结果:4例患者(平均年龄53岁;M:F, 2:2)肝细胞癌合并单肾上腺转移(右肾上腺=2例;左肾上腺=2例)。3例患者在受体手术期间进行肾上腺切除术,而1例患者在肾上腺转移切除术后6个月接受LDLT(表1)。随访时间为9个月至59个月。前两例患者的生存期分别为52个月和59个月。第一位患者发生肺转移,并于术后第52个月因严重败血症而死亡。该系列的第二例患者在肝移植后59个月继续保持无复发生存。第三例和第四例患者的生存期分别为28个月和9个月。第4例患者在组织病理学分析中也有hcc -胆管癌混合。结论:肝细胞癌有限的肝外转移仍然可以切除,如果不能切除肝,总生存率良好,可以进行肝移植。在LT手术中,肾上腺切除术可以作为单阶段手术进行,而不会增加风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信